GlassScriptPhysician profile
Erlinda Grey
NPI 1356568752
$4,216.05
in general payments reported to CMS, 2019-2025
27 companies · $810 in 2025
The $810 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $348 · 2021: $717 · 2022: $636 · 2023: $540 · 2024: $542 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.01 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.04 | 2019-2025 | |
| Lilly USA, LLC | $480.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $315.91 | 2019-2023 | |
| Novo Nordisk INC | $310.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $305.68 | 2019-2025 | Capvaxive, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.77 | 2019-2025 | Jardiance |
| Dexcom, INC. | $247.25 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $205.46 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $204.95 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $198.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Mannkind Corporation | $158.62 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.90 | 2021-2025 | Xifaxan |
| Allergan, INC. | $146.44 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $117.55 | 2019-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $94.34 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.59 | 2019-2021 | |
| Lundbeck LLC | $46.95 | 2023-2024 | Rexulti |
| Alk-Abello, INC | $46.46 | 2025 | Odactra, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $37.67 | 2024 | |
| Pfizer INC. | $37.40 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $25.72 | 2024 | |
| Eisai INC. | $23.29 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.29 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.07 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $19.19 | 2021 | |
| Sanofi Pasteur INC. | $15.67 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erlinda Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.